Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

World Journal of Surgery

Volumn 39, Issue 12, 2015, Pages 2975-2982

  Akahori, Takahiro ^a   Sho, Masayuki ^a   Kinoshita, Shoichi ^a   Nagai, Minako ^a   Nishiwada, Satoshi ^a   Tanaka, Toshihiro ^a   Tamamoto, Tetsuro ^a   Ohbayashi, Chiho ^a   Hasegawa, Masatoshi ^a   Kichikawa, Kimihiko ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; AGED; BACK MUSCLE; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LENGTH OF STAY; LUMBOSACRAL REGION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOGRAPHY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; BACK MUSCLES; CHEMORADIOTHERAPY; FEMALE; HUMANS; LENGTH OF STAY; LUMBOSACRAL REGION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84947026549     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-015-3205-3     Document Type: Article

References (42)

1. Li D, Xie K, Wolff R et al (2004) Pancreatic cancer. Lancet 363:1049-1057
2. Traverso LW (2006) Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 20(Suppl 2):S446-S449
3. Schnelldorfer T, Ware AL, Sarr MG et al (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247:456-462
4. Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701-706
5. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267-277
6. Ueno H, Kosuge T, Matsuyama Y et al (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908-915
7. Satoi S, Yanagimoto H, Toyokawa H et al (2009) Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 38:282-288
8. Sho M, Akahori T, Tanaka T et al (2013) Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 20:197-205
9. Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496-3502
10. Heinrich S, Schafer M, Weber A et al (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248:1014-1022
11. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
12. Ohigashi H, Ishikawa O, Eguchi H et al (2009) Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250:88-95
13. Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960-967
14. Krssak M, Falk Petersen K, Dresner A et al (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:113-116
15. Montani JP, Carroll JF, Dwyer TM et al (2004) Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord 28(Suppl 4):S58-S65
16. Goodpaster BH, Kelley DE, Thaete FL et al (2000) Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89:104-110
17. Taaffe DR, Henwood TR, Nalls MA et al (2009) Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology 55:217-223
18. Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539-1547
19. Sabel MS, Lee J, Cai S et al (2011) Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18:3579-3585
20. Antoun S, Lanoy E, Iacovelli R et al (2013) Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 119:3377-3384
21. Aubrey J, Esfandiari N, Baracos VE et al (2014) Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 210:489-497
22. Anderson DE, D'Agostino JM, Bruno AG et al (2013) Variations of CT-based trunk muscle attenuation by age, sex, and specific muscle. J Gerontol A Biol Sci Med Sci 68:317-323
23. Chang D, Joseph DJ, Ebert MA et al (2014) Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imaging Radiat Oncol 58:223-228
24. Goodpaster BH, Thaete FL, Kelley DE (2000) Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci 904:18-24
25. Kelley DE, Slasky BS, Janosky J (1991) Skeletal muscle density: effects of obesity and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 54:509-515
26. Sho M, Akahori T, Tanaka T et al (2015) Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbecks Arch Surg 400:477-485
27. Sho M, Akahori T, Tanaka T et al (2015) Importance of resectability status in neoadjuvant treatment for pancreatic cancer. J Hepatobiliary Pancreat Sci 22:563-570
28. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Version 2 (2013)
29. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
30. Evans DB, Rich TA, Byrd DR et al (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335-1339
31. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474
32. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Liss, New York
33. Sho M, Tanaka T, Yamada T et al (2011) Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci 18:235-239 discussion 239-240
34. Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629-635
35. Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333-2338
36. Strandberg S, Wretling ML, Wredmark T et al (2010) Reliability of computed tomography measurements in assessment of thigh muscle cross-sectional area and attenuation. BMC Med Imaging 10:18
37. Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504-512
38. Palmer DH, Stocken DD, Hewitt H et al (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14:2088-2096
39. Goodpaster BH, Theriault R, Watkins SC et al (2000) Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 49:467-472
40. Goodpaster BH, Thaete FL, Simoneau JA et al (1997) Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46:1579-1585
41. Pan DA, Lillioja S, Kriketos AD et al (1997) Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983-988
42. Arends J, Bodoky G, Bozzetti F et al (2006) ESPEN Guidelines on Enteral Nutrition: non-surgical oncology. Clin Nutr 25:245-259